Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension

Next Previous
X
Search
Trial Profile

A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LARIAT
  • Sponsors Reata Pharmaceuticals

    • Most Recent Events

    • 11 Oct 2019 According to a Reata Pharmaceuticals media release, safety data from four studies ( NCT03019185, NCT03366337, NCT02316821 and NCT02036970 will be presented at at the American Society of Nephrology Kidney Week 2019 Annual Meeting. Abstract are available on the conference website at https://www.asn-online.org/education/kidneyweek/archives/.
    • 08 Jun 2018 Status changed from active, no longer recruiting to completed.
    • 31 May 2018 This trial has been completed in Spain (end date: 2018-05-16)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top